dc.contributor.author |
Adam, Ahmed
|
|
dc.contributor.author |
Engelbrecht, Matthys J.
|
|
dc.contributor.author |
Bornman, Maria S. (Riana)
|
|
dc.contributor.author |
Manda, S.O.M. (Samuel)
|
|
dc.contributor.author |
Moshokoa, Evelyn M.
|
|
dc.contributor.author |
Feilat, Rasmi A.
|
|
dc.date.accessioned |
2011-06-13T14:15:40Z |
|
dc.date.available |
2011-06-13T14:15:40Z |
|
dc.date.issued |
2011-04 |
|
dc.description.abstract |
OBJECTIVES
• To evaluate the investigational role, ideal
threshold and indications of the Prostate
CAncer gene 3 (PCA3) assay in a South
African context.
• To better define the universality of the
above marker since this is the pioneer study
on the continent of Africa.
PATIENTS AND METHODS
• We prospectively evaluated 105
consecutive South African men referred for a
prostate biopsy at two tertiary centres in the capital city, Pretoria.
• Sequentially, PSA levels and post DRE
urine samples were taken within 24 h before
prostate biopsy.
• The urine specimen was tested using the
PROGENSA TM PCA3 assay and a score was
generated as (PCA3 mRNA/PSA mRNA)× 1000.
• The performance of this assay in
predicting biopsy outcome was assessed,
and compared with that of serum PSA.
RESULTS
• Median patient age was 67 years with a
positive biopsy incidence of 42.9%.
• The higher the PCA3 score the greater the
probability of a positive biopsy (
P
=
0.003).
• This score performed independently of
prostatic volume (
P
=
0.3889) or the
presence of a concurrent primary
malignancy (
P
=
0.804).
• A threshold of 60 revealed a positive
predictive value of 60% with an odds ratio of
4, whereas setting a limit of 35 revealed a
positive predictive value of 54% and odds
ratio of 3.5.
• Using receiver operating characteristics
for overall performance comparison, the PSA
level (area under the curve 0.844) performed
better than the PCA3 score (area under the
curve 0.705).
CONCLUSION
• PCA3 assay has shown consistency and
performed in line with previous studies
but it did not surpass serum PSA in this
population.
• A PCA3 assay threshold of 60 performed
better than the conventional limit of 35.
• This assay may have a potential niche in a
certain subset of South African men that
includes patients with larger glands,
previous negative biopsies and altered
baseline PSA levels. |
en_US |
dc.description.sponsorship |
IlexSA Medical and Lancet Laboratories (South Africa). |
en_US |
dc.identifier.citation |
Adam, A, Engelbrecht, MJ, Borman, MS, Manda, SO, Moshokoa, E & Feilat, RA 2011, 'The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting', BJU International, [http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-410X/issues] |
en_US |
dc.identifier.issn |
1464-4096 (print) |
|
dc.identifier.issn |
1464-410X (online) |
|
dc.identifier.other |
10.1111/j.1464-410X.2011.10202.x |
|
dc.identifier.uri |
http://hdl.handle.net/2263/16831 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Wiley-Blackwell |
en_US |
dc.rights |
© 2011 The Authors ; © 2011 BJU International. The definite version is available at http://onlinelibrary.wiley.com/. This article is embargoed by the publisher until April 2012. |
en_US |
dc.subject |
Biomarker |
en_US |
dc.subject |
Prostate cancer gene 3 |
en_US |
dc.subject |
Prostate histology |
en_US |
dc.subject |
Prostate-specific antigen |
en_US |
dc.subject |
South Africa |
en_US |
dc.subject.lcsh |
Prostate -- Diseases -- Diagnosis -- South Africa |
en |
dc.title |
The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting |
en_US |
dc.type |
Postprint Article |
en_US |